Suppr超能文献

缓激肽对自发性高血压大鼠中血管紧张素转换酶抑制剂雷米普利拉利钠反应的作用。

Contribution by bradykinin to the natriuretic response to the angiotensin converting enzyme inhibitor ramiprilat in spontaneously hypertensive rats.

作者信息

Sakamoto T, Chen C, Lokhandwala M F

机构信息

Department of Pharmacology, College of Pharmacy, University of Houston, TX 77204-5515.

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 1994 Jul;350(1):84-9. doi: 10.1007/BF00180015.

Abstract

It is well documented that angiotensin converting enzyme inhibitors decrease blood pressure, which is associated with natriuresis in humans and certain animal models of hypertension. However, it is not clear whether these beneficial effects are due solely to blockade of angiotensin-II production and/or also involves any contribution by kinins. The present study was performed in Inactin (5-ethyl-5-(1-methylpropyl)-2-thio-barbiturate sodium)-anesthetized spontaneously hypertensive rats aged 10-13 wks to examine the relative influence of the angiotensin receptor antagonist losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1- [(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl] imidazole potassium salt) and the bradykinin receptor 2 antagonist HOE 140 (D-Arg-[Hyp3, Thi5, D-Tic7, Oic8] bradykinin) on renal and hemodynamic responses to the angiotensin converting enzyme inhibitor ramiprilat. We found that ramiprilat (1 mg/kg, i.v.) caused sustained reduction in mean blood pressure, marked increases in urine output and urinary sodium excretion without alteration in glomerular filtration rate. In a separate group of animals, it was found that losartan (1 mg/kg, i.v.) decreased blood pressure to a similar degree as ramiprilat and the magnitude of blood pressure fall seen following the combined administration of ramiprilat and losartan was similar to that caused by either compound alone. However, the increase in urinary sodium excretion seen following losartan administration was significantly smaller than that following ramiprilat or ramiprilat plus losartan.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

有充分的文献记载,血管紧张素转换酶抑制剂可降低血压,这与人体及某些高血压动物模型中的利钠作用相关。然而,目前尚不清楚这些有益作用是否仅归因于血管紧张素II生成的阻断,和/或是否也涉及激肽的作用。本研究在10 - 13周龄的因戊巴比妥钠(5 - 乙基 - 5 -(1 - 甲基丙基)- 2 - 硫代巴比妥酸钠)麻醉的自发性高血压大鼠中进行,以检验血管紧张素受体拮抗剂氯沙坦(2 - 正丁基 - 4 - 氯 - 5 - 羟甲基 - 1 - [(2' -(1H - 四氮唑 - 5 - 基)联苯 - 4 - 基)甲基]咪唑钾盐)和缓激肽受体2拮抗剂HOE 140(D - 精氨酸 - [Hyp3,Thi5,D - Tic7,Oic8]缓激肽)对肾和血流动力学对血管紧张素转换酶抑制剂雷米普利拉反应的相对影响。我们发现,雷米普利拉(1mg/kg,静脉注射)可使平均血压持续降低,尿量和尿钠排泄显著增加,而肾小球滤过率无变化。在另一组动物中,发现氯沙坦(1mg/kg,静脉注射)降低血压的程度与雷米普利拉相似,雷米普利拉和氯沙坦联合给药后血压下降幅度与单独使用任一化合物相似。然而,氯沙坦给药后尿钠排泄的增加明显小于雷米普利拉或雷米普利拉加氯沙坦给药后的增加。(摘要截短为250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验